– USA, CA – Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain, and eye, today announced the appointment of Dr. William Carson, M.D. to its board of directors.
Concurrently, the company announced the appointment of Board member, Thomas Wiggans as new Chairman of the Board, succeeding William Young who retired from the board on February 5, 2021, along with Dr. Carol Gallagher.
“On behalf of Annexon and the board of directors, I am pleased to welcome Dr. Carson to our board,” said Board Chairman, Thomas Wiggans. “As Annexon continues to advance its portfolio of clinical-stage C1q inhibitors, Dr. Carson’s medical background and distinguished experience across therapeutic research, development and commercialization will be important assets to the company. We look forward to his leadership and contributions.”
“I am deeply grateful to both Bill Young and Carol Gallagher for their invaluable service on the Annexon board of directors. Dr. Young joined the board in 2014 and has served as chairman since March 2017. He has been a strong leader and voice on our board, drawing upon his strategic and operational expertise to help guide our scientific and business priorities, and we are delighted that he will continue to provide counsel to Annexon,” said CEO, Douglas Love. “Dr. Gallagher joined the Annexon board in 2018 and has been instrumental in our portfolio and financing strategies over the years.”
About Dr. William Carson
Dr. Carson brings deep expertise in pharmaceutical research, development, and commercialization, with a specialization in central nervous system disorders. Most recently he was the president and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc., leading the development and regulatory approvals of Otsuka’s global compounds.
About Thomas Wiggans
Mr. Wiggans, who succeeds William Young as chairman, has served on the Annexon board of directors since February 2017. Mr. Young retired as chairman of the Annexon board on February 5, 2021, but will continue to be engaged with the company in a consulting capacity.
For more information: https://annexonbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
